BioLineRx Ltd. (BLRX)
Automate Your Wheel Strategy on BLRX
With Tiblio's Option Bot, you can configure your own wheel strategy including BLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BLRX
- Rev/Share 0.0242
- Book/Share 0.0112
- PB 23.7297
- Debt/Equity 1.1173
- CurrentRatio 1.7593
- ROIC -1.1369
- MktCap 319425420.0
- FreeCF/Share -0.0367
- PFCF -7.2717
- PE -34.6411
- Debt/Assets 0.3866
- DivYield 0
- ROE -0.7526
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
3 Stocks Getting Rare Double Upgrades From Analysts
Published: June 06, 2025 by: MarketBeat
Sentiment: Neutral
Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.
Read More
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
Published: May 30, 2025 by: Benzinga
Sentiment: Positive
BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Read More
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Neutral
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - H.C.
Read More
BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
Read More
BioLineRx to Report 2024 Annual Results on March 31, 2025
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.
Read More
About BioLineRx Ltd. (BLRX)
- IPO Date 2011-07-27
- Website https://www.biolinerx.com
- Industry Biotechnology
- CEO Mr. Philip A. Serlin CPA, CPA, M.B.A., MBA
- Employees 28